Pembrolizumab (Keytruda) — CPB 0890 | AETNA Coverage Update

Aetna modified CPB 0890 for pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex), effective January 16, 2026. Here's what changes for billing teams.

This update from Aetna, a CVS Health company, expands the indications list, adds the new subcutaneous formulation Keytruda Qlex, and tightens exclusion criteria across multiple tumor types. Primary billing codes affected include J9271 (pembrolizumab, 1 mg) and HCPCS codes for companion agents, alongside CPT codes 96413 and 96415 for IV infusion administration. If your practice or revenue cycle team manages oncology billing for any Aetna commercial plan, this policy touches nearly every solid tumor and hematologic malignancy you treat.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Pembrolizumab (Keytruda) — CPB 0890
Policy Code	CPB 0890
Change Type	Modified
Effective Date	January 16, 2026
Impact Level	High
Specialties Affected	Medical Oncology, Hematology, Radiation Oncology, Gynecologic Oncology, Urology, Thoracic Surgery, Dermatology
Key Action	Verify precertification and biomarker documentation for all Keytruda claims before submitting against this updated policy

---

Aetna Pembrolizumab Coverage Criteria and Medical Necessity Requirements 2026

The Aetna pembrolizumab coverage policy under CPB 0890 now explicitly covers both the IV formulation (Keytruda) and the new subcutaneous formulation (Keytruda Qlex). This is not a minor administrative refresh. The policy has added indications, restructured criteria for existing indications, and introduced Keytruda Qlex as a billable option alongside J9271 for the IV version.

Precertification is required for all formulations. Call (866) 752-7021 or fax to (888) 267-3277. No precertification means no coverage — period. Build that step into your workflow before the first claim goes out for any patient on this drug.

Aetna also applies its Site of Care Utilization Management Policy to both formulations. That means pembrolizumab billing for infusion at a hospital outpatient department may trigger a site-of-care review, and Aetna can redirect to a lower-cost setting. If your organization has patients currently receiving Keytruda in a hospital outpatient setting, flag those accounts now. A site-of-care denial is a slow-moving revenue problem.

Medical Necessity Criteria by Indication

Aetna considers pembrolizumab medically necessary across a wide range of indications — but each one carries specific conditions. These aren't soft guidelines. Miss a biomarker requirement or a line-of-therapy condition, and you get a denial.

The most common criteria patterns in this coverage policy are:

For cervical cancer, the policy covers three distinct scenarios:

#	Covered Indication Copy
1	Persistent, recurrent, or metastatic disease with chemotherapy ± bevacizumab when PD-L1 CPS ≥1
2	Recurrent or metastatic disease as a single agent or combined with tisotumab vedotin-tftv as subsequent therapy when PD-L1 CPS ≥1, MSI-H, or dMMR
3	FIGO stage III-IVA disease in combination with chemoradiation

Radiation treatment management codes CPT 77427–77470 are listed in CPB 0890 and may apply where pembrolizumab is used in combination with radiation-based regimens. Confirm the specific covered indication with Aetna before billing these codes alongside J9271.

For cutaneous melanoma, coverage includes unresectable or metastatic disease as a single agent, neoadjuvant treatment as a single agent, adjuvant treatment following complete lymph node [criteria — see full source policy for complete language at app.payerpolicy.org/p/aetna/0890], and subsequent therapy in combination with ipilimumab or lenvatinib. CNS brain metastases from melanoma or PD-L1 positive non-small cell lung cancer are also covered as a single agent.

---

Aetna Pembrolizumab Exclusions and Non-Covered Indications

Two hard exclusions apply across all indications in this updated coverage policy.

First: Pediatric members with TMB-H central nervous system cancers are not eligible. This isn't a soft criteria gap — it's a listed exclusion. If you treat pediatric CNS tumor patients and have been billing Keytruda based on TMB-H status, those claims will not survive a review under CPB 0890. Flag any active prior authorizations for this patient population immediately.

Second: Members who experienced disease progression while on a PD-1 or PD-L1 inhibitor are not eligible — with one specific exception. The exception covers subsequent therapy for metastatic or unresectable melanoma in combination with ipilimumab or lenvatinib. That carve-out is narrow. Don't assume it applies broadly to other tumor types.

The real issue with the PD-1/PD-L1 progression exclusion is documentation. Your chart notes must clearly show the patient's prior immunotherapy history and the timing of progression. If that documentation is weak, Aetna has grounds to deny on exclusion grounds even if the clinical scenario fits the exception. Make this part of your precertification checklist now.

---

Coverage Indications at a Glance

---

Aetna Pembrolizumab Billing Guidelines and Action Items 2026

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Pembrolizumab Under CPB 0890

Key HCPCS Codes

Key CPT Codes — Chemotherapy Administration

Key CPT Codes — Radiation Treatment Management

Code	Type	Description Copy
77427–77470	CPT	Radiation treatment management (full range, CPT 77427 through 77470) — listed in CPB 0890; may apply where pembrolizumab is used in combination with radiation-based regimens. Confirm the specific covered indication with Aetna before billing these codes alongside J9271

Key CPT Codes — Biomarker and Pathology Testing

ICD-10-CM Codes

CPB 0890 lists 1,324 ICD-10-CM diagnosis codes. These span all covered tumor types and histologies addressed in the policy — including melanoma, NSCLC, cervical cancer, Hodgkin lymphoma, anal carcinoma, ampullary adenocarcinoma, and CNS metastases, among others. Review the full code list in the source document at app.payerpolicy.org/p/aetna/0890 and confirm that each patient's diagnosis code maps to a covered indication before submitting. A claim denial from a non-covered ICD-10 is entirely avoidable — and completely on the billing team.

---